* The company has begun a new investment of 11.9 million US dollars in a high-quality modern laboratory
American company GlaxoSmithKline has completed investments of seven million Euros in two production lines at the plant it owns in Braşov, and will become the only company in the pharmaceutical business to domestically manufacture brands known worldwide on a local level, Pascal Prigent, the CEO of GSK Romania announced yesterday. The investments have taken place over the last three years and have targeted the manufacturing of the drugs Seroxat (antidepressants) and Retrovir capsules (anti-HIV). Also this year, the company began investments of 11.9 million dollars into a high-quality certification laboratory, which will be completed by the end of 2012.
Once the investments are completed, GSK Romania is looking to increase its exports from 60% to 75% of its total output. Moreover, the number of tablets manufactured in Braşov is set to increase this year from 42 million to 46 million units, the aforementioned source said. In 2010, the plant produced a volume of 42.3 million units, a 57% increase over 2009.
According to Prigent, since entering the Romanian market in 1998, GSK invested 120 million dollars on the local market, with most of that amount going to the plant of Braşov (USD 100 million).
Up until three years ago, the plant of Braşov only manufactured local brands of drugs, those of Europharm which were intended exclusively for the local market. Right now, over 60% of the output gets exported to 50 countries, with the most important being Italy and France, as well as Japan, and the company is expecting to sell the drugs manufactured in Romania in 80 countries starting next year. "For GSK, the plant of Braşov represents the perfect combination between the quality of people which work here and competitive costs. In the future we wis
